Micaela Romagnoli

Chief, MD, PhD

Azienda ULSS 2 Marca Trevigiana

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Micaela Romagnoli is a Chief and MD, PhD at Azienda ULSS 2 Marca Trevigiana in Italy. Her research focuses on severe eosinophilic asthma and its treatment strategies, with recent publications examining the clinical outcomes of therapies such as Dupilumab, Mepolizumab, and Benralizumab. Additionally, she has investigated the complications of severe COVID-19, contributing to a deeper understanding of the disease's impact on respiratory health.

Articles (6)

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2021

Year:

2020

Collaborators (2)

Gianenrico Senna

University of Verona

ITALY

View details

Simonetta Baraldo

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Micaela Romagnoli

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Determinants of Clinical Remission in Dupilumab-Treated Severe Eosinophilic Asthma: A Real-World Retrospective Study

Mepolizumab-Related Blood Eosinophil Decreases Are Associated with Clinical Remission in Severe Asthmatic Patients: A Real-World Study

Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma

Multidimensional 3-Month Follow-Up of Severe COVID-19: Airways beyond the Parenchyma in Symptomatic Patients

Pneumothorax and/or Pneumomediastinum Worsens the Prognosis of COVID-19 Patients with Severe Acute Respiratory Failure: A Multicenter Retrospective Case-Control Study in the North-East of Italy

Reply to Wand et al.: Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases: An Ongoing Tale

Collaborators (2)

Gianenrico Senna

Simonetta Baraldo

Make your next move.